Cameron Turtle

Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA.

Navire Pharma, Inc. engages in the development of therapeutics to treat multiple cancers. It focuses on SHP2, a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signalling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. The company was founded by Phil Jones and Benjamin Neel in 2017 and is headquartered in San Francisco, CA.

Part of BridgeBio Pharma, Inc., CoA Therapeutics, Inc. is a biotechnology company based in San Francisco, CA. The private company is targeting coenzyme-A (CoA) for patients with PKAN, organic acidurias, and other diseases of CoA sequestration. CoA plays a crucial role in energy metabolism and is implicated in a large number of disorders, from ultra-rare diseases like pantothenate kinase-associated neurodegeneration (PKAN) and organic acidurias (OAs), to common diseases such as type 2 diabetes. CoA Therapeutics is developing a novel small-molecule approach to modulate CoA levels by leveraging recent research about the CoA synthetic pathway. The company's approach and lead compounds are based on breakthrough scientific developments led by Suzanne Jackowski, Charles Rock, Richard Lee, and Stephen White at St. Jude Children's Research Hospital.

Part of BridgeBio Pharma, Inc., Fortify Therapeutics, Inc. is a private company dedicated to developing a safe and effective treatment for patients with Leber's hereditary optic neuropathy (LHON), a rare mitochondrial genetic disorder that leads to loss of central vision predominantly in young adults. The company is based in Palo Alto, CA. LHON is driven by mutations in subunits of the NADH dehydrogenase complex, reducing the ability of the retinal cells to produce energy, resulting in their degeneration. Fortify Therapeutics is currently developing a localized therapy to bypass the dysfunctional metabolic pathway in this disease and provide an alternate source of energy to the retinal cells of LHON patients.